1-4 of 4
Jesper Haaning, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events

Stephanie Valer Seremetis, MD, Katarina Cepo, MD, Josephine Skovgaard Rasmussen, DVM, Trine Høyer Rose, PhD, Søren Tamer, MSc, Thomas Porstmann, PhD, Jesper Haaning, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40.
https://doi.org/10.1182/blood-2020-139563
Published: 2020
Journal Articles

Waveform Analysis Extends the Capabilities of aPTT and PT Clotting Assays for Detecting Factor Deficiency and Monitoring Procoagulant Drug Therapy

Lilley Leong, PhD, MS, Xiaoqiao Jiang, BS, Jill Cifrese, MS, John E. Murphy, PhD, Jesper Haaning, PhD, Timothy Myles, PhD
Journal: Blood
Blood (2011) 118 (21): 1205.
https://doi.org/10.1182/blood.V118.21.1205.1205
Published: 2011
Journal Articles

BAY 94–9027, a PEGylated Recombinant Human FVIII, Shows Less Immunogenicity Compared to Un-PEGylated Recombinant FVIII

Inge A Ivens, PhD., D.A.B.T., Ruprecht Zierz, PhD, Jesper Haaning, PhD, Thomas McDonald, MPH, PhD
Journal: Blood
Blood (2010) 116 (21): 2214.
https://doi.org/10.1182/blood.V116.21.2214.2214
Published: 2010
Journal Articles

Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study of the rFVIIa Variant (BAY 86–6150) In Hemophilia A or B with or without Inhibitors.

J.N. Mahlangu, MBBCH, FCPath, MMed, M.J. Coetzee, MBChB, MMed(Path), FFPath(SA), DTM&H, M. Laffan, DM, FRCP, FRCPath, J. Windyga, MD, PhD, T. T. Yee, MD, J. Schroeder, MD, PhD, Jesper Haaning, PhD, J.E. Siegel, MD, G. Lemm, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3679.
https://doi.org/10.1182/blood.V116.21.3679.3679
Published: 2010